Fluconazole Pharmacokinetics in Burn Patients

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 1998 Apr 29

PMID 9559811

Citations 12

Authors

B A Boucher

S R King

H L Wandschneider

W L Hickerson

S D Hanes

V L Herring

T W Canada

M M Hess

Affiliations

Soon will be listed here.

Abstract

The pharmacokinetics of fluconazole in nine adult patients with severe (30 to 95% total body surface area) burns were studied. There was no significant difference in half-life (t1/2), clearance (CL), or volume of distribution (V) over time in five patients on days 3 and 8 of the study (P > 0.05). Combined parameter estimates (means +/- standard deviations) for all nine patients for the two study periods were as follows: t1/2, 24.4 +/- 5.8 h; CL, 0.36 +/- 0.09 ml/min/kg; and V, 0.72 +/- 0.12 liters/kg. These estimates of t1/2 and CL in burn patients were approximately 13% shorter and 30% more rapid, respectively, than the most extreme estimates reported for other populations.

Citing Articles

Changes in fluconazole pharmacokinetics can impact on antifungal effectiveness in critically ill burn patients: a Pharmacokinetic-Pharmacodynamic (PK/PD) approach.

Matsuno V, Campos E, Silva Junior E, Silva Junior J, Gomez D, Santos S Clinics (Sao Paulo). 2024; 79:100491.

PMID: 39316893 PMC: 11462178. DOI: 10.1016/j.clinsp.2024.100491.

Evaluation of Voriconazole and Posaconazole Dosing in Patients With Thermal Burn Injuries.

Musick K, Jones S, Norris A, Hochstetler L, Williams F, McKinzie B J Burn Care Res. 2021; 43(4):802-807.

PMID: 34672325 PMC: 9391605. DOI: 10.1093/jbcr/irab200.

Developmental changes of fluconazole clearance in neonates and infants in relation to ontogeny of glomerular filtration rate: literature review and data analysis.

Murakoso K, Minagawa R, Echizen H J Pharm Health Care Sci. 2018; 4:5.

PMID: 29568540 PMC: 5859487. DOI: 10.1186/s40780-018-0103-5.

Comparative Population Plasma and Tissue Pharmacokinetics of Micafungin in Critically Ill Patients with Severe Burn Injuries and Patients with Complicated Intra-Abdominal Infection.

Garcia-de-Lorenzo A, Luque S, Grau S, Agrifoglio A, Cachafeiro L, Herrero E Antimicrob Agents Chemother. 2016; 60(10):5914-21.

PMID: 27458229 PMC: 5038299. DOI: 10.1128/AAC.00727-16.

[Not Available].

Arnould J, Le Floch R Ann Burns Fire Disasters. 2015; 28(1):21-8.

PMID: 26668558 PMC: 4665176.

References

Sawchuk R, Zaske D . Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: gentamicin in burn patients. J Pharmacokinet Biopharm. 1976; 4(2):183-95. DOI: 10.1007/BF01086153. View

Zaske D, Sawchuk R, Gerding D, Strate R . Increased dosage requirements of gentamicin in burn patients. J Trauma. 1976; 16(10):824-8. DOI: 10.1097/00005373-197610000-00014. View

Loirat P, Rohan J, Baillet A, Beaufils F, David R, Chapman A . Increased glomerular filtration rate in patients with major burns and its effect on the pharmacokinetics of tobramycin. N Engl J Med. 1978; 299(17):915-9. DOI: 10.1056/NEJM197810262991703. View

Zaske D, Sawchuk R, Strate R . The necessity of increased doses of amikacin in burn patients. Surgery. 1978; 84(5):603-8. View

Fraser V, Jones M, Dunkel J, Storfer S, Medoff G, Dunagan W . Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis. 1992; 15(3):414-21. DOI: 10.1093/clind/15.3.414. View

Ripa S, Ferrante L, Prenna M . Pharmacokinetics of fluconazole in normal volunteers. Chemotherapy. 1993; 39(1):6-12. DOI: 10.1159/000238967. View

Debruyne D, Ryckelynck J . Clinical pharmacokinetics of fluconazole. Clin Pharmacokinet. 1993; 24(1):10-27. DOI: 10.2165/00003088-199324010-00002. View

Rex J, Bennett J, Sugar A, Pappas P, van der Horst C, Edwards J . A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med. 1994; 331(20):1325-30. DOI: 10.1056/NEJM199411173312001. View

Goa K, Barradell L . Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Drugs. 1995; 50(4):658-90. DOI: 10.2165/00003495-199550040-00007. View

10.

Bourget P, Le Reveille R, Le Bever H, Carsin H . Clinical pharmacokinetics of piperacillin-tazobactam combination in patients with major burns and signs of infection. Antimicrob Agents Chemother. 1996; 40(1):139-45. PMC: 163072. DOI: 10.1128/AAC.40.1.139. View

11.

Spebar M, LINDBERG R . Fungal infection of the burn wound. Am J Surg. 1979; 138(6):879-82. DOI: 10.1016/0002-9610(79)90315-5. View

12.

Spebar M, PRUITT Jr B . Candidiasis in the burned patient. J Trauma. 1981; 21(3):237-9. DOI: 10.1097/00005373-198103000-00007. View

13.

Brater D, Bawdon R, Anderson S, Purdue G, Hunt J . Vancomycin elimination in patients with burn injury. Clin Pharmacol Ther. 1986; 39(6):631-4. DOI: 10.1038/clpt.1986.111. View

14.

Prasad J, Feller I, Thomson P . A ten-year review of Candida sepsis and mortality in burn patients. Surgery. 1987; 101(2):213-6. View

15.

Desai M, Herndon D, Abston S . Candida infection in massively burned patients. J Trauma. 1987; 27(10):1186-8. DOI: 10.1097/00005373-198710000-00016. View

16.

Pensler J, Herndon D, Ptak H, Bonds E, Rutan T, Desai M . Fungal sepsis: an increasing problem in major thermal injuries. J Burn Care Rehabil. 1986; 7(6):488-91. View

17.

Garrelts J, Peterie J . Altered vancomycin dose vs. serum concentration relationship in burn patients. Clin Pharmacol Ther. 1988; 44(1):9-13. DOI: 10.1038/clpt.1988.105. View

18.

Foulds G, Brennan D, Wajszczuk C, Catanzaro A, Garg D, Knopf W . Fluconazole penetration into cerebrospinal fluid in humans. J Clin Pharmacol. 1988; 28(4):363-6. DOI: 10.1002/j.1552-4604.1988.tb03159.x. View

19.

Wey S, Mori M, Pfaller M, Woolson R, Wenzel R . Hospital-acquired candidemia. The attributable mortality and excess length of stay. Arch Intern Med. 1988; 148(12):2642-5. DOI: 10.1001/archinte.148.12.2642. View

20.

Walstad R, Aanderud L, Thurmann-Nielsen E . Pharmacokinetics and tissue concentrations of ceftazidime in burn patients. Eur J Clin Pharmacol. 1988; 35(5):543-9. DOI: 10.1007/BF00558251. View